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Abstract
Background: We evaluate the role of nerve growth factor (NGF) eye drops to treat a herpetic
corneal ulcer resistant to systemic and local acyclovir treatment in an HIV-positive patient.
Case Presentation: A 68 year old HIV-positive male presented with a herpetic corneal ulcer
which was treated unsuccessfully with acyclovir. Acyclovir sensitivity of herpes simplex virus was
tested with a dye uptake assay and we found that the herpes simplex virus isolated was resistant
to acyclovir. We started eye drop therapy with NGF and the corneal herpetic ulcer healed in 23
treatment days.
Conclusion: The case presented here is the first described in the literature in which a herpetic
corneal ulcer was successfully treated with NGF. We recommend that trials of NGF therapy in
herpetic keratitis should be carried out on a larger number of acyclovir resistant cases.
Background
Herpes simplex virus (HSV-1) infections of the eye, and in
particular keratitis, are quite frequent in people with
acquired immunodeficiency syndrome [1] and are gener-
ally treated with acyclovir. Recently, there has been a pro-
gressive increase in the number of cases resistant to
acyclovir [2] due to the development of viral strains resist-
ant to the drug and the appearance of a gene tk mutation
[3]. Experimental studies have recently demonstrated that
nerve growth factor (NGF) is able to block HSV-1 reactiva-
tion [4] and is also able to repair neurotrophic corneal
ulcers [5]. On the basis of this, we decided to use NGF eye
drops to treat a corneal herpetic ulcer in an HIV-positive
patient, where the herpes simplex virus was resistant to
systemic and local acyclovir treatment.
Case presentation
A male patient, aged 68 years, was referred to us in Octo-
ber 2004 with a corneal herpetic ulcer in his right eye. The
ulcer had appeared after an influenza vaccination. The
anamnesis showed that the patient was HIV-positive with-
out signs of AIDS and with a CD4 count of 496/mm3. Fur-
thermore he was not on Highly Active Anti-Retroviral
Treatment (HAART). We treated the patient with oral acy-
clovir, 800 mg five times daily, and topical acyclovir oint-
ment four times daily. After 10 days of treatment no
clinical improvement was observed (Fig. 1). We collected
a sample of corneal cells that was found to be positive for
HSV-1. The sensitivity of the isolated HSV-1 to acyclovir
was tested using a dye uptake assay that measured the
quantitative cytopathic effect [6] and we found that HSV-
1 isolates were resistant to acyclovir.
On the basis of the persistence of the corneal herpetic
ulcer we decided to discontinue the topical and systemic
acyclovir therapies and to trial topical treatment with NGF
eye drops. Before treatment the patient was informed of
the procedures and the aim of the therapy and he signed
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a written consent form. The institutional ethics committee
of the S. Orsola-Malpighi Hospital also approved the
study.
Treatment consisted of murine NGF purified from sub
maxillary glands and produced in the laboratories of the
Institute of Neurobiology & Molecular Medicine (CNR-
EBR, Roma, Italy).
We administered NGF eye drops (10 µg NGF dissolved in
50 µL saline solution and 0.9% sodium chloride) every
two hours in the inferior conjunctival fornix until the
ulcer was healed, which occurred after 23 days of treat-
ment (Fig. 2). After healing, we continued treatment for
another 15 days, reducing the administration of eye drops
to just 4 times daily. A year after the treatment with NGF
eye drops, the patient was reviewed and there was no sign
of recurrent keratitis
Conclusion
This case illustrates the appearance of HSV-1 viral strains
resistant to acyclovir [2]. Acyclovir is a potent and highly
selective antiviral nucleoside analog, which remains one
of the standard treatments of HSV infections in both
immunocompetent and immunocompromised hosts. To
become active and inhibit viral DNA synthesis acyclovir
must be phosphorylated to acyclovir monophosphate by
specific HSV-1 thymidine kinases (tk) and then phospho-
rylated to acyclovir triphosphate, the active form of acy-
clovir able to inhibit viral DNA-polymerases, by host cell
kinases.
Previous studies indicate that antiviral resistance develops
at a stable low rate in pools of HIV. Acyclovir-resistance is
based principally on three different mechanisms [7]. Two
mechanisms involve a deficiency of viral tk genes, the
third shows drug resistance with normal expression of tk.
These mutants have either an altered tk enzyme or a muta-
tion in their DNA polymerase gene [7].
NGF is a member of the neurotrophin gene family which
also includes neurotrophin 3 (NT-3), neurotrophin 4/5
(NT-4) and brain-derived neurotrophic factor (BDNF).
Neurotrophins exert their biological functions by binding
to high affinity transmembranous receptors belonging to
the trk family of receptor tyrosin kinase including trkA,
trkB and trkC and p75 [8].
TrkA is the receptor of NGF and consists of a 140 KD mol-
ecule, which modulates not just neuronal survival but
also the migration and proliferation of other cell lines [8].
NGF is a polypeptide that is essential for the survival and
growth of sympathetic and sensorial system neurons and
for CNS neuronal differentiation [8]. The production of
NGF and the ubiquitous presence of its specific receptors
have also been demonstrated in the ocular surfaces [9].
The mechanism of action of NGF on the ocular surface to
heal corneal neurotrophic ulceration is not well defined.
It may be that NGF restores a deficit of synthesis or release
of endogenous NGF [5]. A direct mechanism may involve
the sensory innervation and the proliferation and differ-
entiation of epithelial cells [10]. An indirect mechanism
could be related to the increase of those neuropeptides
that promote epithelial healing or the release of cytokines.
In vitro and in vivo studies [10] have shown how the
depletion of NGF causes a reactivation of HSV-1. This
Healing of corneal herpetic ulcer after treatment with nerve  growth factor eye drops Figure 2
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reactivation is the consequence of the loss of balance
between the cytokine produced by the corneal epithelial
inflammation and the resulting reduction in the NGF-trkA
complex signals [4]. Topical administration of NGF has
therefore a mainly anti-inflammatory effect blocking the
action of the cytokine and restoring the normal transmis-
sion of the NGF-trkA complex towards the nerve endings
[10].
The case presented here is the first described in the medi-
cal literature in which a corneal herpetic ulcer, resistant to
antiviral therapy, was treated with NGF. Although the use
of NGF for the treatment of this type of disorder is still
under debate, we believe that its use in selected cases of
herpetic keratitis resistant to acyclovir therapy must be
investigated on a larger number of cases to confirm our
result.
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